




Toxoplasmosis Among HIV Patients and Healthy Volunteers in Port Harcourt, Rivers State, Nigeria

Evelyn O Onosakponome¹, Austin E Abah ^{2,*} and Michael Wogu²

¹Department of Medical Laboratory Science, Pamo University of Medical Sciences, Port Harcourt, Nigeria

²Department of Animal and Environmental Biology, University of Port Harcourt, Port Harcourt, Nigeria

*Corresponding author: Department of Animal and Environmental Biology, University of Port Harcourt, Port Harcourt, Nigeria. Email: austin.abah@uniport.edu.ng

Received 2020 March 30; Revised 2020 May 23; Accepted 2020 May 30.

Abstract

Background: Toxoplasmosis is a serious infection, especially among the immune-compromised people such as HIV/AIDS patients.

Objectives: This study assessed the seroprevalence and associated risk factors of toxoplasmosis among HIV patients and healthy volunteers or immuno-competent persons (IP) in Port Harcourt.

Methods: A total of 400 (200 per group) randomly-selected sera were tested for IgG and IgM *T. gondii* antibodies using ELISA technique. CD4 cell counts were also determined. Demographic and risk factors were determined using a well-structured questionnaire.

Results: Overall seroprevalence for HIV and IP using IgG and IgM toxoplasma antibodies was 36.0%, 21.5%, and 1.5%, 7.0%, respectively. The age group of 40 years and above had the highest seroprevalence of 25.3% among the HIV positive persons, while the age groups 25 - 29 years had the highest seroprevalence of 20.0% among the IP. Traders' positive with HIV had the highest seroprevalence of 30.0% and 0.9% for IgG and IgM toxoplasma antibodies, respectively. HIV subjects with a secondary education showed the highest seroprevalence of 20.0%. More HIV positive females were infected with toxoplasmosis 18.5%. In all, 6.7% ($P > 0.05$) of the seropositive patients had CD4 cell counts of less than 200 cells/ μ L, indicating no correlation between seroprevalence and CD4 cell counts of HIV/AIDS patients. Risk factors in this study included the history of living with pets, farming and eating improperly-washed fruits and vegetables.

Conclusions: Seroprevalence of Toxoplasmosis was high among HIV patients in Port Harcourt. It is suggested that the institutions included the Toxoplasmosis test as one of the routine tests for HIV patients.

Keywords: Toxoplasmosis, Seroprevalence, HIV Patients, Immuno-Competent, Antibodies

1. Background

Toxoplasmosis is an important but neglected tropical parasitic infection with global distribution and significance (1-3). It is caused by the protozoa called *Toxoplasma gondii* (4). Cats and other feline species are the definitive host as these animals excrete the oocysts into the environment (5). Also, humans become infected by eating food or drinking water contaminated with oocysts released in cat feces (1, 6, 7). In humans with normal immune competence, *Toxoplasma* spp. infections tend to be asymptomatic in most cases. This is not the case in individuals who are immuno-compromised as acute infections or reactivation of a latent infection can be severe and life-threatening, causing severe encephalitis with fatal consequences (7-9).

Toxoplasmosis is gaining much prominence economically, medically, and epidemiologically (8, 9). Establishing the link between toxoplasmosis and immune competence is vital, considering the increasing number of immuno-

compromised patients, including HIV positive patients, cancer patients, and organ transplant recipients. The parasite can lead to life-threatening conditions for these individuals, being an opportunistic parasite. Hence, the need to generate baseline data that will assist health institutions to make policies on whether toxoplasmosis testing should be included in daily routine laboratory testing or not. Especially in Nigeria, where toxoplasma testing is not carried out in the health care centers as routine. Such data may also determine the most efficient method to adopt for detecting the parasite.

2. Objectives

The main objective of this study was to investigate the seroprevalence and risk factors of *Toxoplasma gondii* among healthy volunteers and immunocompromised subjects drawn from - the HIV clinics of the University of Port Harcourt Teaching Hospital and the Braithwaite

Memorial Specialist Hospital both in Port Harcourt, Rivers State, Nigeria.

3. Methods

3.1. Description of Study Area

Braithwaite Memorial Specialist Hospital (BMSH), also known as Rivers State University Teaching Hospital (RSUTH), is located on 5 - 8 Harley Street, old GRA, Port Harcourt, Rivers State, Nigeria. It is located within latitude 4°46'49" North and 7°0'50" East. It was established in 1925 as Braithwaite Memorial Hospital and originally served as a medical facility for senior civil servants. It later became a general hospital and gained the status as a "Specialist Health Institution". It is now one of the biggest referral hospitals owned by the State Government in Rivers State.

The University of Port Harcourt Teaching Hospital is located in East-West Road, a few kilometers from the University of Port Harcourt, Port Harcourt. Both hospitals are owned by the government, attract many people with different societal status.

3.2. Collection of Samples and Serological Testing

Three millimeters of venous blood was collected from each of the 200 participants between February and June 2016. The blood samples were allowed to clot and then centrifuged for 5 minutes at (1500) rpm. The sera were collected and stored at 2°C. The developing plates cards, reagents, and specimen were all brought to a temperature of 24°C. These were processed using Bio Check for Toxoplasma Immunoglobulins IgG and IgM enzyme immunoassay test kit following standard methods. The number of CD4+ T-lymphocyte for each patient was measured and documented by the flow cytometry procedure.

3.3. Demographic Data Collection

A well-structured questionnaire capturing information regarding age, gender, occupation, possession of pets, and other risk factors were administered to respondents.

3.4. Ethical Considerations

Ethical clearance was sought and obtained from the ethical committees of the University of Port Harcourt Teaching Hospital and Rivers State Hospital Management Board. Written informed consent was also obtained from the subjects.

3.5. Data Analysis

A two-way factor ANOVA and mean separation were used to analyze the data generated from this study.

4. Results

The overall seroprevalence and socio-demographic factor-related seroprevalence in the study population are shown in Table 1. Out of the 400 (200 per group) examined, HIV recorded a higher seroprevalence of 36.0% compared to IP with 21.5% for IgG ELISA tests. Also, HIV positive people recorded a seroprevalence of 1.5% compared to IP with 7.0% for ELISA IgM tests, respectively. The seroprevalence of IgG was found to be statistically significant ($P < 0.05$) while that of IgM was insignificant ($P > 0.05$). Age groups of 40 years and above had the highest seroprevalence of 25.3% - for HIV, while age groups 25 - 29 years had the highest seroprevalence of 20.0% - for IP. Occupationally-related prevalence showed that traders positive with HIV had the highest seroprevalence 30.0% and 0.9% followed by the artisans positive with HIV 23.6% and 1.8% for IgG and IgM Toxoplasma antibodies. Traders had the highest seroprevalence among IP with 14.5% and 4.6% followed by students 11.8% and 3.2% for IgG and IgM Toxoplasma antibodies, respectively. HIV subjects with a secondary education showed the highest seroprevalence 20.0% for IgG ELISA tests, while IP subjects with tertiary education had the highest seroprevalence 14.0% for the same IgG antibodies. More Positive HIV females 18.5% and 0.8% were infected with the disease for IgG and IgM tests. More IP females 13.6% and 3.8% - were infected with the disease for IgG and IgM tests. The number of CD4 cells related to seroprevalence showed that there was no noteworthy difference between the *T. gondii* seropositivity with the CD4+ lymphocyte count. Table 2 shows the risk factors affecting the transmission of Toxoplasmosis in this study.

5. Discussion

The study showed that the HIV subjects recorded a higher seroprevalence with 36.0% compared to IP 21.5% for IgG ELISA tests. Also, HIV subjects recorded a seroprevalence of 1.5% compared to IP with 7.0% for ELISA IgM tests respectively. This result is similar to reports of the other studies of seroprevalence rate, 40.8% in Western Iran (9), 36.3% in Mazandaran, Iran (10), and 32.4% in Zaria, Nigeria (11). However, the seroprevalence of toxoplasmosis in HIV-positive subjects showed a little variation in some other studies, including 20%, 22.2%, and 27% which were reported in Eastern Nigeria, Abuja, Nigeria, and Sudan respectively (8, 11, 12). Seropositivity of 27% was reported for *T. gondii* among healthy immunocompetent people in Mali, Africa (13), while some studies reported a higher seroprevalence of 44.9%, 49.1%, 60.7%, and 80.8% (14-17). These discrepancies may be due to differences in their way of life, geographical area, weather conditions, and prevailing socio-

Table 1. Seroprevalence Based on Socio-Demographic Factors Among the Study Population^a

Factor /Parameter	NE	Number Positive (%)			
		IP		HIV	
		IgG	IgM	IgG	IgM
Overall	400	45 (21.5)	14 (7.0)	72 (36.0)	3 (1.5)
Age group					
20 -24	56	4 (7.1)	3 (5.4)	8 (14.2)	2 (3.6)
25 -29	75	15 (20.0)	2 (2.7)	13 (17.3)	1 (1.3)
30 -34	105	11 (10.5)	4 (3.8)	18 (17.1)	1 (0.9)
35 -39	85	8 (9.4)	4 (4.3)	13 (15.3)	1 (1.2)
> 40	79	5 (6.3)	1 (1.3)	20 (25.3)	0 (0.0)
Occupation					
Artisan	55	5 (9.1)	3 (5.5)	13 (23.6)	1 (1.8)
Civil servant	56	5 (8.9)	1 (1.8)	6 (10.7)	0 (0.0)
Farmer	12	0 (0.0)	1 (8.3)	2 (16.7)	0 (0.0)
Student	93	12 (12.0)	3 (3.2)	6 (6.5)	1 (1.1)
Teacher	38	8 (21.1)	1 (2.6)	4 (10.5)	0 (0.0)
Trader	110	13 (11.8)	5 (4.6)	33 (30.0)	1 (0.0)
Unemployed	36	0 (0.0)	0 (0.0)	8 (22.2)	0 (0.0)
Educational status					
Primary	40	6 (15.0)	2 (5.0)	15 (37.5)	0 (0.0)
Secondary	160	9 (5.6)	5 (3.2)	32 (20.0)	2 (1.3)
Tertiary	200	28 (14.0)	7 (3.5)	25 (12.5)	1 (0.5)
Sex					
Female	265	26 (15.0)	8 (3.0)	44 (16.6)	2 (0.8)
Male	135	17 (12.6)	6 (4.4)	28 (20.7)	1 (0.7)
CD4					
< 200	105			0.7 (6.7)	0 (0.0)
200 - 399	115			18 (15.7)	1 (0.9)
400 - 599	70			10 (14.3)	0 (0.0)
> 600	110			35 (31.8)	2 (1.8)

Abbreviations: IgG, Immunoglobulin G-toxoplasma ELISA test; IgM, Immunoglobulin M-toxoplasma ELISA test; IP, immunocompetent subjects; HIV, immunocompromised subjects; NE, number examined

^aP = 0.9044 (P < 0.05).

demographic factors prompting the spread of the parasite in these localities.

This study showed fewer rates of IgM seroprevalence (3%) P > 0.05 than IgG. This observation supports the fact that IgM *Toxoplasma* antibody reaction to *Toxoplasma* infection is low; it is often repressed to untraceable levels in cases of severe immunosuppression (15). Similar observations of lower IgM seroprevalence compared to IgG seropositivity in HIV patients were also reported by other researchers from India (16, 17), Mexico (18), South Africa (19), Northern (11), and Western Iran (9). The low proportions of IgM antibodies in HIV positive subjects show that the testing for this antibody in the routine diagnosis of *T. gondii*

infection in non-pregnant HIV infected individuals may be of restricted value (9). Also, the suppressed toxoplasmosis does not present any symptoms (8).

Nazari et al. (9), in a similar study, reported that seroprevalence was the highest in the 46 - 60 year age group, whereas Zhang et al. showed that the highest prevalence of the disease was in 3rd and 4th decades of life (20). Nevertheless, Walle et al. reported the highest prevalence rate in the 21 - 30-year age group (21). These deviations can probably be expounded by the long exposure time as the patient continues to age. Although there were no significant correlations between age groups and the seroprevalence of *Toxoplasma* spp., it was observed that the seroprevalence of *Toxoplasma* spp. infection increases with age ascribed to the waning immunity and gradual inception of aging (8, 13). The work-related prevalence showed that the traders with HIV had the highest seroprevalence of 30.0% and 0.9%, followed by the artisans with HIV 23.6% and 1.8% for IgG, and IgM *Toxoplasma* antibodies. Traders had the highest seroprevalence for IP 14.5% and 4.6%, followed by students 11.8% and 3.2% for IgG and IgM *Toxoplasma* antibodies, respectively. In this study, seropositivity was not significantly swayed by occupation and educational level. This is comparable to the previously-made observations in the related studies (8, 9, 11, 21).

HIV positive females recorded a higher seroprevalence (18.5%) than HIV positive males (17.0%) and IP females and males. However, the seroprevalence rates were close to those obtained in similar findings in Abuja (8), Malaysia (9), Western Iran (9), and Northern Mexico (17), showing that *T. gondii* seroprevalence was not sex-related.

There was no significant difference between the *T. gondii* seropositivity with the CD4+ lymphocyte count, which is consistent with the reports of studies from Northern Nigeria, Ethiopia, Malaysia, Mexico and Morocco (11, 15, 18, 21) However, according to a study in Jahrom, Iran, there was a correlation between the CD4+ count, 100 cells/ μ L and the *Toxoplasma* seropositivity (22). Although CD4+ T cells played a major role in fortification against intracellular protozoan parasites such as *T. gondii* as the cells produce important effector cells that help control the parasite recrudescence during HIV infection (23, 24).

History of keeping pets, engaging in gardening, and farming and eating improperly washed fruits and vegetables were factors that significantly influenced the spread of toxoplasmosis in this study. This is supported by the findings reported in other studies (8, 9, 25, 26). From the similar studies which border on risk factors which influence toxoplasmosis, it has also been observed that Poor personal hygiene which greatly contributes to toxoplasmosis, is not considered (27-29).

Toxoplasmosis is prevalent in HIV positive patients in

Table 2. Seroprevalence of Toxoplasmosis Among HIV Subjects and Healthy Volunteers Based on Associated Risk Factors in Port Harcourt

Risk Factors	NE	NP IgG		NP IgM		Mean Separation ^a
		IP	HIV	IP	HIV	
Engage in farming						
Yes	242 (60.50)	19 (9.50)	36 (18.00)	4 (2.00)	2 (1.00)	1.68 ^A
No	158 (39.50)	24 (12.00)	36 (18.00)	10 (5.00)	1 (0.50)	1.38 ^A
Wash fruits						
Yes	116 (29.00)	12 (6.00)	16 (8.00)	3 (1.50)	0 (0.00)	0.42 ^B
No	284 (71.00)	31 (15.50)	57 (28.50)	11 (5.50)	3 (1.50)	0.89 ^A
Drink treated water						
Yes	73 (18.25)	14 (7.00)	0 (0.00)	3 (1.50)	0 (0.00)	1.13 ^B
No	327 (81.75)	29 (14.50)	72 (36.00)	11 (5.50)	3 (1.50)	1.88 ^A
History of owning pets						
Yes	124 (31.00)	8 (4.00)	44 (22.00)	2 (1.00)	0.5 (0.25)	0.80 ^A
No	276 (69.00)	35 (17.50)	27.5 (13.75)	12 (6.00)	2.5 (1.25)	0.75 ^A
Consume Suya						
Yes	51 (12.75)	7 (3.50)	3 (1.50)	5 (2.50)	0 (0.00)	0.67 ^A
No	350 (87.50)	36 (18.00)	70 (35.00)	9 (4.50)	3 (1.50)	1.05 ^A

Abbreviations: IgG, Immunoglobulin G-Toxoplasma ELISA; IgM, Immunoglobulin M-Toxoplasma ELISA; IP, Immunocompetent Persons; HIV, Immunocompromized subjects; NE, Number Examined; NP, Total number positive to *Toxoplasma gondii*
^a Means that do not share a letter are significantly different $P < 0.05$ ($P < 0.05$).

Port Harcourt and evident as suppressed symptomatic infections in the healthy populace. We recommend a regular awareness campaign in the study area. We also recommend regular testing of all HIV infected individuals for IgG anti-toxoplasma antibodies for timely detection of patients who may be at risk of the infection.

Footnotes

Authors’ Contribution: EOO and AEA conceived and designed the work, EOO, and MW acquired the data and analyzed it. EOO drafted the manuscript, AEA Revised it for important content. All the authors read and approved the manuscript.

Conflict of Interests: The authors declare that there is no conflict of interest.

Ethical Approval: Ethical clearance was sought and obtained from the ethical committees of the University of Port Harcourt Teaching Hospital and Rivers State Hospital Management Board.

Funding/Support: None.

Informed Consent: Written informed consent was also obtained from the subjects.

References

- Jones JL, Dubey JP. Foodborne toxoplasmosis. *Clin Infect Dis.* 2012;**55**(6):845–51. doi: [10.1093/cid/cis508](https://doi.org/10.1093/cid/cis508). [PubMed: [22618566](https://pubmed.ncbi.nlm.nih.gov/22618566/)].
- Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of *Toxoplasma gondii* seroprevalence and implications for pregnancy and congenital toxoplasmosis. *Int J Parasitol.* 2009;**39**(12):1385–94. doi: [10.1016/j.ijpara.2009.04.003](https://doi.org/10.1016/j.ijpara.2009.04.003). [PubMed: [19433092](https://pubmed.ncbi.nlm.nih.gov/19433092/)].
- Schluter D, Daubener W, Schares G, Gross U, Pleyer U, Luder C. Animals are key to human toxoplasmosis. *Int J Med Microbiol.* 2014;**304**(7):917–29. doi: [10.1016/j.ijmm.2014.09.002](https://doi.org/10.1016/j.ijmm.2014.09.002). [PubMed: [25240467](https://pubmed.ncbi.nlm.nih.gov/25240467/)].
- Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev.* 2012;**25**(2):264–96. doi: [10.1128/CMR.05013-11](https://doi.org/10.1128/CMR.05013-11). [PubMed: [22491772](https://pubmed.ncbi.nlm.nih.gov/22491772/)]. [PubMed Central: [PMC3346298](https://pubmed.ncbi.nlm.nih.gov/PMC3346298/)].
- Dubey JP, Jones JL. *Toxoplasma gondii* infection in humans and animals in the United States. *Int J Parasitol.* 2008;**38**(11):1257–78. doi: [10.1016/j.ijpara.2008.03.007](https://doi.org/10.1016/j.ijpara.2008.03.007). [PubMed: [18508057](https://pubmed.ncbi.nlm.nih.gov/18508057/)].
- L’Ollivier C, Wallon M, Faucher B, Piarroux R, Peyron F, Franck J. Comparison of mother and child antibodies that target high-molecular-mass *Toxoplasma gondii* antigens by immunoblotting improves neonatal diagnosis of congenital toxoplasmosis. *Clin Vaccine Immunol.* 2012;**19**(8):1326–8. doi: [10.1128/CVI.00060-12](https://doi.org/10.1128/CVI.00060-12). [PubMed: [22695159](https://pubmed.ncbi.nlm.nih.gov/22695159/)]. [PubMed Central: [PMC3416078](https://pubmed.ncbi.nlm.nih.gov/PMC3416078/)].
- Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. *Psychol Med.* 2013;**43**(2):239–57. doi: [10.1017/S0033291712000736](https://doi.org/10.1017/S0033291712000736). [PubMed: [22717193](https://pubmed.ncbi.nlm.nih.gov/22717193/)]. [PubMed Central: [PMC3479084](https://pubmed.ncbi.nlm.nih.gov/PMC3479084/)].
- Uttah EC, Ajang R, Ogbeche J, Etta H, Etim L. Comparative seroprevalence and risk factors of toxoplasmosis among three subgroups in Nigeria. *J Nat Sci Res.* 2013;**3**:23–8.

9. Nazari N, Bozorgomid A, Janbakhsh A, Bashiri F. Toxoplasma gondii and human immunodeficiency virus co-infection in western Iran: A cross sectional study. *Asian Pacific J Trop Med*. 2018;**11**(1):58. doi: [10.4103/1995-7645.223562](https://doi.org/10.4103/1995-7645.223562).
10. Rahimi MT, Mahdavi SA, Javadian B, Rezaei R, Moosazadeh M, Khademlou M, et al. High Seroprevalence of Toxoplasma gondii Antibody in HIV/AIDS Individuals from North of Iran. *Iran J Parasitol*. 2015;**10**(4):584-9. [PubMed: [26811725](https://pubmed.ncbi.nlm.nih.gov/26811725/)]. [PubMed Central: [PMC4724835](https://pubmed.ncbi.nlm.nih.gov/PMC4724835/)].
11. Ogoina D, Onyemelukwe GC, Musa BO, Obiako RO. Seroprevalence of IgM and IgG antibodies to Toxoplasma infection in healthy and HIV-positive adults from Northern Nigeria. *J Infect Dev Ctries*. 2013;**7**(5):398-403. doi: [10.3855/jidc.2797](https://doi.org/10.3855/jidc.2797). [PubMed: [23669429](https://pubmed.ncbi.nlm.nih.gov/23669429/)].
12. Mustafa M, Fathy F, Mirghani A, Mohamed MA, Muneer MS, Ahmed AE, et al. Prevalence and risk factors profile of seropositive Toxoplasmosis gondii infection among apparently immunocompetent Sudanese women. *BMC Res Notes*. 2019;**12**(1):279. doi: [10.1186/s13104-019-4314-0](https://doi.org/10.1186/s13104-019-4314-0). [PubMed: [31097016](https://pubmed.ncbi.nlm.nih.gov/31097016/)]. [PubMed Central: [PMC6524216](https://pubmed.ncbi.nlm.nih.gov/PMC6524216/)].
13. Uneke CJ, Duhlińska DD, Njoku MO, Ngwu BA. Seroprevalence of acquired toxoplasmosis in HIV-infected and apparently healthy individuals in Jos, Nigeria. *Parasitologia*. 2005;**47**(2):233-6. [PubMed: [16252478](https://pubmed.ncbi.nlm.nih.gov/16252478/)].
14. Ouologuem DT, Djimde AA, Diallo N, Doumbo OK, Roos DS. Toxoplasma gondii seroprevalence in Mali. *J Parasitol*. 2013;**99**(2):371-4. doi: [10.1645/GE-3239.1](https://doi.org/10.1645/GE-3239.1). [PubMed: [22924926](https://pubmed.ncbi.nlm.nih.gov/22924926/)]. [PubMed Central: [PMC6810635](https://pubmed.ncbi.nlm.nih.gov/PMC6810635/)].
15. Nissapatorn V, Kamarulzaman A, Init I, Tan LH, Rohela M, Norliza A, et al. Seroepidemiology of toxoplasmosis among HIV-infected patients and healthy blood donors. *Med J Malaysia*. 2002;**57**(3):304-10. [PubMed: [12440270](https://pubmed.ncbi.nlm.nih.gov/12440270/)].
16. Sukthana Y. Toxoplasmosis: beyond animals to humans. *Trends Parasitol*. 2006;**22**(3):137-42. doi: [10.1016/j.pt.2006.01.007](https://doi.org/10.1016/j.pt.2006.01.007). [PubMed: [16446116](https://pubmed.ncbi.nlm.nih.gov/16446116/)].
17. Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, et al. Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. *Acta Trop*. 2014;**137**:185-94. doi: [10.1016/j.actatropica.2014.05.015](https://doi.org/10.1016/j.actatropica.2014.05.015). [PubMed: [24887263](https://pubmed.ncbi.nlm.nih.gov/24887263/)].
18. Gongora-Biachi RA, Gonzalez-Martinez P, Castro-Sansores C, Alvarez-Moguel R, Pavia-Ruz N, Lara-Perera D, et al. [Antibodies against Toxoplasma gondii in patients with HIV in Yucatan]. *Rev Invest Clin*. 1998;**50**(5):419-22. Spanish. [PubMed: [9949673](https://pubmed.ncbi.nlm.nih.gov/9949673/)].
19. Hari KR, Modi MR, Mochan AH, Modi G. Reduced risk of toxoplasma encephalitis in HIV-infected patients-a prospective study from Gauteng, South Africa. *Int J STD AIDS*. 2007;**18**(8):555-8. doi: [10.1258/095646207781439829](https://doi.org/10.1258/095646207781439829). [PubMed: [17686219](https://pubmed.ncbi.nlm.nih.gov/17686219/)].
20. Zhang YB, Cong W, Li ZT, Bi XG, Xian Y, Wang YH, et al. Seroprevalence of Toxoplasma gondii Infection in Patients of Intensive Care Unit in China: A Hospital Based Study. *Biomed Res Int*. 2015;**2015**:908217. doi: [10.1155/2015/908217](https://doi.org/10.1155/2015/908217). [PubMed: [25961046](https://pubmed.ncbi.nlm.nih.gov/25961046/)]. [PubMed Central: [PMC4415447](https://pubmed.ncbi.nlm.nih.gov/PMC4415447/)].
21. Walle F, Kebede N, Tsegaye A, Kassa T. Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia. *Parasit Vectors*. 2013;**6**(1):15. doi: [10.1186/1756-3305-6-15](https://doi.org/10.1186/1756-3305-6-15). [PubMed: [23324409](https://pubmed.ncbi.nlm.nih.gov/23324409/)]. [PubMed Central: [PMC3556116](https://pubmed.ncbi.nlm.nih.gov/PMC3556116/)].
22. Rezanezhad H, Sayadi F, Shadmand E, Nasab SD, Yazdi HR, Solhjoo K, et al. Seroprevalence of Toxoplasma gondii among HIV Patients in Jahrom, Southern Iran. *Korean J Parasitol*. 2017;**55**(1):99-103. doi: [10.3347/kjp.2017.55.1.99](https://doi.org/10.3347/kjp.2017.55.1.99). [PubMed: [28285515](https://pubmed.ncbi.nlm.nih.gov/28285515/)]. [PubMed Central: [PMC5365268](https://pubmed.ncbi.nlm.nih.gov/PMC5365268/)].
23. Zhou P, Chen Z, Li HL, Zheng H, He S, Lin RQ, et al. Toxoplasma gondii infection in humans in China. *Parasit Vectors*. 2011;**4**:165. doi: [10.1186/1756-3305-4-165](https://doi.org/10.1186/1756-3305-4-165). [PubMed: [21864327](https://pubmed.ncbi.nlm.nih.gov/21864327/)]. [PubMed Central: [PMC3174123](https://pubmed.ncbi.nlm.nih.gov/PMC3174123/)].
24. Kodym P, Maly M, Beran O, Jilich D, Rozsypal H, Machala L, et al. Incidence, immunological and clinical characteristics of reactivation of latent Toxoplasma gondii infection in HIV-infected patients. *Epidemiol Infect*. 2015;**143**(3):600-7. doi: [10.1017/S0950268814001253](https://doi.org/10.1017/S0950268814001253). [PubMed: [24850323](https://pubmed.ncbi.nlm.nih.gov/24850323/)].
25. Tekkesin N. Diagnosis of toxoplasmosis in pregnancy: a review. *HOAJ Biology*. 2012;**1**(1):9. doi: [10.7243/2050-0874-1-9](https://doi.org/10.7243/2050-0874-1-9).
26. Alvarado-Esquivel C, Liesenfeld O, Burciaga-Lopez BD, Ramos-Nevarez A, Estrada-Martinez S, Cerrillo-Soto SM, et al. Seroepidemiology of Toxoplasma gondii infection in elderly people in a northern Mexican city. *Vector Borne Zoonotic Dis*. 2012;**12**(7):568-74. doi: [10.1089/vbz.2011.0875](https://doi.org/10.1089/vbz.2011.0875). [PubMed: [22448744](https://pubmed.ncbi.nlm.nih.gov/22448744/)].
27. Wang ZD, Wang SC, Liu HH, Ma HY, Li ZY, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis. *Lancet HIV*. 2017;**4**(4):e177-88. doi: [10.1016/S2352-3018\(17\)30005-X](https://doi.org/10.1016/S2352-3018(17)30005-X). [PubMed: [28159548](https://pubmed.ncbi.nlm.nih.gov/28159548/)].
28. Feleke DG, Gebreweld A, Zewde G. Toxoplasmosis in Pregnant Women and HIV/AIDS Patients in Ethiopia: A Systematic Review and Meta-Analysis. *J Parasitol Res*. 2019;**2019**:4670397. doi: [10.1155/2019/4670397](https://doi.org/10.1155/2019/4670397). [PubMed: [31662891](https://pubmed.ncbi.nlm.nih.gov/31662891/)]. [PubMed Central: [PMC6791202](https://pubmed.ncbi.nlm.nih.gov/PMC6791202/)].
29. Wilking H, Thamm M, Stark K, Aebischer T, Seeber F. Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. *Sci Rep*. 2016;**6**:22551. doi: [10.1038/srep22551](https://doi.org/10.1038/srep22551). [PubMed: [26936108](https://pubmed.ncbi.nlm.nih.gov/26936108/)]. [PubMed Central: [PMC4776094](https://pubmed.ncbi.nlm.nih.gov/PMC4776094/)].